Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 10:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: West Syndrome Clear all
Terminated Phase 3 Interventional Results available

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

NCT04485104
View directory record Official record
Conditions
Seizure in Participants With Tuberous Sclerosis Complex, Seizure in Participants With Dravet Syndrome, Seizure in Participants With Lennox-Gastaut Syndrome
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 23 Months
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns

NCT00006396
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day and older
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2004
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 3, 2026, 10:25 AM EDT
Completed No phase listed Observational

Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT01146210
View directory record Official record
Conditions
Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Fanconi Anemia, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults

NCT00442169
View directory record Official record
Conditions
West Nile Fever
Interventions
ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose, 0.9% Saline solution, 0.9 % NaCl solution
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
5
States / cities
Phoenix, Arizona • Idaho Falls, Idaho • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 3, 2026, 10:25 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients

NCT03976076
View directory record Official record
Conditions
Refractory Infantile Spasms
Interventions
JBPOS0101
Drug
Lead sponsor
Bio-Pharm Solutions Co., Ltd.
Industry
Eligibility
6 Months to 36 Months
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)

NCT02953548
View directory record Official record
Conditions
Infantile Spasms
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Little Rock, Arkansas • Winston-Salem, North Carolina • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults

NCT04723602
View directory record Official record
Conditions
Ebola Virus Disease, Marburg Virus Disease
Interventions
cAd3-Marburg, cAd3-EBO-S
Biological
Lead sponsor
Albert B. Sabin Vaccine Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Sep 3, 2026, 10:25 AM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate Safety and Efficacy of AMZ002 Treatment, Compared With Vigabatrin in Participants With Infantile Spasms

NCT05128344
View directory record Official record
Conditions
Spasms, Infantile
Interventions
AMZ002 injectable solution, 0.5mg/mL, Vigabatrin, oral
Drug
Lead sponsor
Amzell
Industry
Eligibility
2 Months to 24 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Aurora, Colorado • Miami, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Sep 3, 2026, 10:25 AM EDT
Terminated Phase 2 Interventional Results available

Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

NCT02551731
View directory record Official record
Conditions
Spasms, Infantile
Interventions
Cannabidiol Oral Solution
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
6 Months to 36 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Not applicable Interventional

Assisted Partner Services and HIVST in Western Kenya

NCT04774835
View directory record Official record
Conditions
Hiv
Interventions
HIVST, Standard aPS
Diagnostic Test
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
4,941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Sep 3, 2026, 10:25 AM EDT
Recruiting Phase 2 Interventional

Treatment of Refractory Infantile Spasms With Fenfluramine

NCT04289467
View directory record Official record
Conditions
Infantile Spasm
Interventions
Fenfluramine
Drug
Lead sponsor
Children's Hospital of Orange County
Other
Eligibility
12 Months to 36 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 4 Interventional

Evaluation of Neuroinflammation in Children With Infantile Spasms

NCT02092883
View directory record Official record
Conditions
Infantile Spasms
Interventions
ACTH
Drug
Lead sponsor
Wayne State University
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)

NCT02954887
View directory record Official record
Conditions
Infantile Spasms
Interventions
GWP42003-P
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Month to 24 Months
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Little Rock, Arkansas • Winston-Salem, North Carolina • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 3, 2026, 10:25 AM EDT
Completed No phase listed Observational

Genetic Studies in Patients and Families With Infantile Spasms

NCT01723787
View directory record Official record
Conditions
Infantile Spasms
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Days to 21 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 3, 2026, 10:25 AM EDT
Recruiting Phase 1 Interventional

Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies

NCT06700811
View directory record Official record
Conditions
Developmental and Epileptic Encephalopathies, Epileptic Spasms, Genetic Epilepsy, Neonatal and Infant Epilepsy
Interventions
Ketogenic diet
Drug
Lead sponsor
Heather Olson
Other
Eligibility
0 Days to 9 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 3, 2026, 10:25 AM EDT
Suspended Phase 3 Interventional

A Novel Approach to Infantile Spasms

NCT03347526
View directory record Official record
Conditions
Infantile Spasm
Interventions
Cosyntropin Injectable Suspension, 1 mg/mL, Cosyntropin Injectable Suspension 1 MG/ML + vigabatrin, Vigabatrin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Months to 2 Years
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated May 26, 2021 · Synced Sep 3, 2026, 10:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)

NCT01808352
View directory record Official record
Conditions
HIV
Interventions
Observational
Other
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
18 Years and older · Male only
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Sep 3, 2026, 10:25 AM EDT
Completed No phase listed Observational

Epilepsy Phenome/Genome Project

NCT00552045
View directory record Official record
Conditions
Epilepsy, Localization-related Epilepsy, Infantile Spasms, Lennox-Gastaut Syndrome, Polymicrogyria, Periventricular Heterotopias
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
4 Weeks to 60 Years
Enrollment
4,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2018 · Synced Sep 3, 2026, 10:25 AM EDT
Terminated Phase 2 Interventional Results available

Open-label Extension to Protocol 1042-0500

NCT00442104
View directory record Official record
Conditions
Infantile Spasms
Interventions
Ganaxolone
Drug
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
4 Months to 24 Months
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 27, 2024 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

NCT03650452
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
Interventions
TAK-935, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Sep 3, 2026, 10:25 AM EDT
Terminated Not applicable Interventional

Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)

NCT01367964
View directory record Official record
Conditions
West Syndrome
Interventions
adrenocorticotropin hormone
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
2 Months to 12 Months
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 3, 2026, 10:25 AM EDT
Recruiting Phase 2 Interventional

A Study to Prevent Infantile Spasms Relapse

NCT06819670
View directory record Official record
Conditions
Infantile Spasms, Infantile Epileptic Spasms Syndrome, West Syndrome
Interventions
Prednisolone, Famotidine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
2 Months to 18 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Sep 3, 2026, 10:25 AM EDT
Completed Phase 2 Interventional Results available

A Randomized, Controlled Trial of Ganaxolone in Patients With Infantile Spasms

NCT00441896
View directory record Official record
Conditions
Infantile Spasms
Interventions
Ganaxolone, Placebo
Drug · Other
Lead sponsor
Marinus Pharmaceuticals
Industry
Eligibility
4 Months to 24 Months
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2023 · Synced Sep 3, 2026, 10:25 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms

NCT03421496
View directory record Official record
Conditions
Infantile Spasm
Interventions
Cannabidiol Oral Solution, Placebo, Vigabatrin
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
1 Month to 24 Months
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Miami, Florida • Royal Oak, Michigan • Akron, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced Sep 3, 2026, 10:25 AM EDT